title: [Therapeutic intensification and autologous stem cell transplantation in autoimmune diseases].
abstract: THE PATHOPHYSIOLOGY of most autoimmune diseases is often poorly understood. EXPERIMENTAL CONSIDERATIONS and clinical experience suggest that high doses immunoablation followed by stem cell transplantation is a therapeutic option to consider for certain severe autoimmune disorders. THE CONCEPT OF RESTORING NORMAL IMMUNE REACTIVITY must in part br true since current results of 466 transplants (445 autologous, 21 allogeneic) patients suffering from various autoimmune diseases show a beneficial outcome in approximately 2/3 of the patients. TO IMPROVE THE EFFICACY AND SAFETY OF SUCH AN AGGRESSIVE PROCEDURE in patients with potentially affected vital organs by the underlying autoimmune disease, it is especially important to follow international consensus guidelines and to centrally collect clinical data for in depth analysis in the EBMT International Stem Cell Project for Autoimmune Disease in Basel, Switzerland. PHASE III STUDIES ARE RUNNING FOR SYSTEMIC SCLEROSIS (Astis, Autologous Stem cell Transplantation International Rheumatoid Arthritis Trial) started in 2003. A STUDY PROJECT IS PLANNED FOR MULTIPLE SCLEROSIS (Astims, Autologous Stem cell Transplantation International Multiple Sclerosis).
authors.affiliation: Service de médecine interne, Service de greffe de moelle, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010 Paris, France.
authors.forename: Z
authors.initials: Z
authors.lastname: Marjanovic
authors.forename: I
authors.initials: I
authors.lastname: Gerber
authors.forename: C
authors.initials: C
authors.lastname: Toledano
authors.forename: J
authors.initials: J
authors.lastname: Hen-Solal
authors.forename: R
authors.initials: R
authors.lastname: Damade
authors.forename: I
authors.initials: I
authors.lastname: de Saint-Cyr
authors.forename: F
authors.initials: F
authors.lastname: Sarrot-Reynauld
authors.forename: D
authors.initials: D
authors.lastname: Ilié
authors.forename: M
authors.initials: M
authors.lastname: Daneshpouy
authors.forename: N
authors.initials: N
authors.lastname: Mounier
authors.forename: M
authors.initials: M
authors.lastname: Ruivard
authors.forename: C
authors.initials: C
authors.lastname: Tyndall
authors.forename: E
authors.initials: E
authors.lastname: Vidal
authors.forename: I
authors.initials: I
authors.lastname: Quere
authors.forename: J-M
authors.initials: JM
authors.lastname: Durand
authors.forename: J
authors.initials: J
authors.lastname: Constans
authors.forename: D
authors.initials: D
authors.lastname: Farge
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D005240:Feasibility Studies; D006801:Humans; D007223:Infant; D051379:Mice; D008875:Middle Aged; D018579:Patient Selection; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome